Catherine Callaghan Coombs, MD, discusses the mechanism of action of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.
Catherine Callaghan Coombs, MD, an assistant professor of medicine in the Division of Hematology at the University of North Carolina School of Medicine, discusses the mechanism of action of pirtobrutinib (LOXO-305) in chronic lymphocytic leukemia and small lymphocytic leukemia.
According to Coombs, pirtobrutinib is a non-covalent BTK inhibitor, meaning it binds to the same target ibrutinib (Imbruvica) and acalabrutinib (Calquence) do. However, unlike ibrutinib and acalabrutinib, pirtobrutinib does this in a non-covalent fashion. This means that the activity of pirtobrutinib is independent of the presence of absence of the C481 mutations, which is the most common mechanism of resistance to ibrutinib and acalabrutinib.
In addition to this, pirtobrutinib has a very clean pharmacokinetic profile. According to Coombs, the agent has liner responses based on dosing and is effective at binding above IC90 for all doses above 100 milligrams daily.
0:08 | Pirtobrutinib is a non-covalent BTK inhibitor so it binds the same target as ibrutinib and acalabrutinib. However, it does so in a non-covalent fashion. The advantage of this is that its activity is independent of the presence or absence of the C481 mutations which are the most common mechanism of resistance to ibrutinib and acalabrutinib. The other advantage of the drug is that it has a very clean pharmacokinetic profile with linear responses based on the dosing and it is effective at binding above IC90 for all doses above 100 milligrams daily
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More